Tata Capital Healthcare Fund invests $20 million in Orbicular Pharmaceutical Technologies

The specialty generics has a market size of $60 billion and is rapidly expanding, driven by increasing demand for cost-effective alternatives to complex and high-cost branded medications. “Under the able leadership of Dr. M.S. Mohan, Orbicular has developed a strong product pipeline for the regulated markets," said Visalakshi Chandramouli, managing partner, Tata Capital Healthcare Fund.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8TRjamY
via IFTTT